SUBSCRIBE
SUBSCRIBE

Daiichi Sankyo

Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical therapies to improve standards of care and address diversified, unmet medical needs of people globally by leveraging our world-class science and technology.

With more than 100 years of scientific expertise and a presence in more than 20 countries, Daiichi Sankyo and its 15,000 employees around the world draw upon a rich legacy of innovation and a robust pipeline of promising new medicines to help people. In addition to a strong portfolio of medicines for cardiovascular diseases, under the Group’s 2025 Vision to become a “Global Pharma Innovator with Competitive Advantage in Oncology,” Daiichi Sankyo is primarily focused on providing novel therapies in oncology, as well as other research areas centered around rare diseases and immune disorders.

For more information, please visit: www.daiichisankyo.com.

Daiichi Sankyo, Inc., headquartered in Basking Ridge, New Jersey, is a member of the Daiichi Sankyo Group. To learn more about Daiichi Sankyo, Inc., please visit www.dsi.com.

  • 2025 BPTW Badge - RBG.png
  • 2024 - Best Places to Work - Badges - Brighspot Rework - Outlined - 20pt.png
211 Mt. Airy Road
Basking Ridge, NJ 07920
Tel: (908) 992-6400
Visit website
  • Featured Employer
NEWS
Podcasts
FDA Approves Lilly’s Donanemab While Rejections Highlight Manufacturing Issues
Two CRLs from the FDA last week cited concerns with third-party manufacturers, while Indian CDMOs may make a bid for U.S. business if there is a decoupling from Chinese companies under the BIOSECURE Act.
July 3, 2024
 · 
1 min read
 · 
Jef Akst
Business partners discussing the terms of a contract
Patents
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: 3D illustration of antibody-drug conjugates carrying toxic payloads
Drug Development
AstraZeneca, Daiichi Sankyo ADC Misses Endpoint in Phase III NSCLC Study
AstraZeneca and Daiichi Sankyo’s investigational antibody-drug conjugate Dato-DXd failed to significantly improve overall survival in non-small cell lung cancer patients versus docetaxel.
May 28, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: An antibody-drug conjugate under construction by two scientists/ Nicole Bean for BioSpace
Drug Development
Despite Progress, ADCs Still Stalled in Non-Small Cell Lung Cancer
Until compelling surface targets for lung cancer are developed, antibody-drug conjugates will fail to treat most patients with lung cancer, experts told BioSpace.
May 20, 2024
 · 
5 min read
 · 
Mollie Barnes
AstraZeneca's sign on its office in California
Drug Development
AstraZeneca, Daiichi Sankyo Continue Earlier-Line Breast Cancer Push with Phase III Enhertu Win
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu significantly improved progression-free survival in metastatic breast patients with low and ultralow HER2 expression levels who had received at least one line of systemic treatment.
April 30, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Female scientist uses microscope for lab
Job Trends
5 Top Companies Hiring Oncology Jobs
Looking for oncology jobs in the biopharma industry? Check out these five top companies hiring life sciences professionals like you.
April 17, 2024
 · 
1 min read
 · 
Angela Gabriel
Pictured: FDA signage at its office in Washington, DC
FDA
AstraZeneca, Daiichi Sankyo Win First Tumor-Agnostic HER2 FDA Approval for Enhertu
AstraZeneca and Daiichi Sankyo’s antibody-drug conjugate Enhertu is the first FDA-approved tumor-agnostic HER2-targeted therapy authorized for the treatment of solid tumors in adults who have undergone prior systemic treatment.
April 8, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Office building science collage
Job Trends
The Top 11 Companies Hiring in Biopharma Now
Looking for a biopharma job? Check out the BioSpace list of 11 top companies hiring life sciences professionals like you.
April 3, 2024
 · 
1 min read
 · 
Angela Gabriel
Pictured: A pattern of ADCs, tumors and IV bags
Drug Development
The Next Wave of ADCs Could Treat Evasive Solid Tumors
With second-generation antibody-drug conjugates, Eli Lilly, Daiichi Sankyo and others look to reduce toxicity and improve the magnitude and duration of response.
April 2, 2024
 · 
6 min read
 · 
Heather McKenzie
Load More
JOBS
View All Jobs at Daiichi Sankyo
IN THE PRESS
Press Releases
Datopotamab Deruxtecan New BLA Submitted for Accelerated Approval in the U.S. for Patients with Previously Treated Advanced EGFR-Mutated Non-Small Cell Lung Cancer
November 12, 2024
 · 
10 min read
Press Releases
ENHERTU® Receives Prestigious 2024 Prix Galien USA Award for Best Biotechnology Product
November 8, 2024
 · 
19 min read
Press Releases
Three Phase 3 Trials of Datopotamab Deruxtecan-Based Combinations Initiated in Patients with Advanced Nonsquamous Non-Small Cell Lung Cancer
October 30, 2024
 · 
11 min read
Press Releases
Latest AMRA Medical Research in Muscle & Nerve Demonstrates The Utility of MRI-based Biomarkers In Inflammatory Myopathies
October 25, 2024
 · 
3 min read
Press Releases
ENHERTU® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low or HER2-ultralow metastatic breast cancer who have received at least one line of endocrine therapy
October 1, 2024
 · 
19 min read
Press Releases
ENHERTU® Granted Priority Review in the U.S. for Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer Who Have Received at Least One Line of Endocrine Therapy
October 1, 2024
 · 
19 min read
Press Releases
Final Real-World Results from MILOS German Cohort Demonstrate Strong Increase in LDL-C Goal Achievement With Addition of Bempedoic Acid
September 27, 2024
 · 
9 min read
Press Releases
Datopotamab Deruxtecan Final Overall Survival Results Reported in Patients with Metastatic HR Positive, HER2 Low or Negative Breast Cancer in TROPION-Breast01 Phase 3 Trial
September 23, 2024
 · 
19 min read
Press Releases
DS-9606 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors
September 16, 2024
 · 
7 min read
Drug Development
ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy
June 2, 2024
 · 
39 min read
Load More